Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival - PubMed (original) (raw)
. 2008 Feb 20;3(2):e1651.
doi: 10.1371/journal.pone.0001651.
Tatiana Dracheva, Melissa Rotunno, Jonine D Figueroa, Huaitian Liu, Abhijit Dasgupta, Felecia E Mann, Junya Fukuoka, Megan Hames, Andrew W Bergen, Sharon E Murphy, Ping Yang, Angela C Pesatori, Dario Consonni, Pier Alberto Bertazzi, Sholom Wacholder, Joanna H Shih, Neil E Caporaso, Jin Jen
Affiliations
- PMID: 18297132
- PMCID: PMC2249927
- DOI: 10.1371/journal.pone.0001651
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival
Maria Teresa Landi et al. PLoS One. 2008.
Abstract
Background: Tobacco smoking is responsible for over 90% of lung cancer cases, and yet the precise molecular alterations induced by smoking in lung that develop into cancer and impact survival have remained obscure.
Methodology/principal findings: We performed gene expression analysis using HG-U133A Affymetrix chips on 135 fresh frozen tissue samples of adenocarcinoma and paired noninvolved lung tissue from current, former and never smokers, with biochemically validated smoking information. ANOVA analysis adjusted for potential confounders, multiple testing procedure, Gene Set Enrichment Analysis, and GO-functional classification were conducted for gene selection. Results were confirmed in independent adenocarcinoma and non-tumor tissues from two studies. We identified a gene expression signature characteristic of smoking that includes cell cycle genes, particularly those involved in the mitotic spindle formation (e.g., NEK2, TTK, PRC1). Expression of these genes strongly differentiated both smokers from non-smokers in lung tumors and early stage tumor tissue from non-tumor tissue (p<0.001 and fold-change >1.5, for each comparison), consistent with an important role for this pathway in lung carcinogenesis induced by smoking. These changes persisted many years after smoking cessation. NEK2 (p<0.001) and TTK (p = 0.002) expression in the noninvolved lung tissue was also associated with a 3-fold increased risk of mortality from lung adenocarcinoma in smokers.
Conclusions/significance: Our work provides insight into the smoking-related mechanisms of lung neoplasia, and shows that the very mitotic genes known to be involved in cancer development are induced by smoking and affect survival. These genes are candidate targets for chemoprevention and treatment of lung cancer in smokers.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
Figure 1. Comparison of gene expression differentiating current from never smokers (C/N) and gene expression differentiating former from never smokers (F/N) in early stage tumor tissue (T) using Gene Set Enrichment Analysis (GSEA).
Left: Running Enrichment Score (y axis) is calculated by walking down the entire list of probes from Affymetrix HG-U133A chip (numbered from 1 to 22,283 in the x axis) ordered by the ANOVA coefficients divided by the standard error values from the Former/Never (F/N) smoking comparison. This running-sum statistic increases when a given probe is in the Current/Never (C/N) Gene Set of interest and decreases when the probe is not in the C/N Gene Set, with the magnitude of increment depending on the strength of the correlation between the probe and the F/N comparison. The Enrichment Score (ES) is the maximum deviation of the Running Enrichment Score from zero encountered in the random walk and reflects the degree to which the Gene Set is overrepresented at the extremes (top or bottom) of the entire ranked probe list. We report results for two different C/N Gene Sets: on the top, the 64 up-regulated probes, with ES = 0.87 and, on the bottom, the 98 down-regulated probes, with ES = −0.90. A leading edge subset of the Gene Set is defined as those probes in the Gene Set that appear in the probes ranked list at, or before, the point where the running sum reaches its maximum deviation from zero. The leading edge for the Gene Set of the C/N up-regulated probes contains 58 probes over 64 and the leading edge for the Gene Set of down-regulated probes contains 90 over 98 probes. This confirms that among the 64 up-regulated probes from the C/N comparison, 58 are also found in the F/N comparison; and among the 98 down-regulated probes from the C/N comparison, 90 are also found in the F/N comparison. Right: distributions of ES values created using a permutation procedure for (top) the Gene Set of up-regulated probes in C/N and (bottom) the Gene Set of down-regulated probes in C/N. These distributions are used to calculate the statistical significance (nominal p-value) of the observed ES values (p-value<0.002 in both cases).
Similar articles
- Relation between smoking history and gene expression profiles in lung adenocarcinomas.
Staaf J, Jönsson G, Jönsson M, Karlsson A, Isaksson S, Salomonsson A, Pettersson HM, Soller M, Ewers SB, Johansson L, Jönsson P, Planck M. Staaf J, et al. BMC Med Genomics. 2012 Jun 7;5:22. doi: 10.1186/1755-8794-5-22. BMC Med Genomics. 2012. PMID: 22676229 Free PMC article. - Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.
Woenckhaus M, Klein-Hitpass L, Grepmeier U, Merk J, Pfeifer M, Wild P, Bettstetter M, Wuensch P, Blaszyk H, Hartmann A, Hofstaedter F, Dietmaier W. Woenckhaus M, et al. J Pathol. 2006 Oct;210(2):192-204. doi: 10.1002/path.2039. J Pathol. 2006. PMID: 16915569 - Genomic and transcriptional alterations in lung adenocarcinoma in relation to smoking history.
Karlsson A, Ringnér M, Lauss M, Botling J, Micke P, Planck M, Staaf J. Karlsson A, et al. Clin Cancer Res. 2014 Sep 15;20(18):4912-24. doi: 10.1158/1078-0432.CCR-14-0246. Epub 2014 Jul 18. Clin Cancer Res. 2014. PMID: 25037737 - Expression profiling and lung cancer development.
Borczuk AC, Powell CA. Borczuk AC, et al. Proc Am Thorac Soc. 2007 Jan;4(1):127-32. doi: 10.1513/pats.200607-143JG. Proc Am Thorac Soc. 2007. PMID: 17202302 Review. - Mechanisms of Disease: signal transduction in lung carcinogenesis -- a comparison of smokers and never-smokers.
Mountzios G, Fouret P, Soria JC. Mountzios G, et al. Nat Clin Pract Oncol. 2008 Oct;5(10):610-8. doi: 10.1038/ncponc1181. Epub 2008 Jul 15. Nat Clin Pract Oncol. 2008. PMID: 18628738 Review.
Cited by
- scParser: sparse representation learning for scalable single-cell RNA sequencing data analysis.
Zhao K, So HC, Lin Z. Zhao K, et al. Genome Biol. 2024 Aug 16;25(1):223. doi: 10.1186/s13059-024-03345-0. Genome Biol. 2024. PMID: 39152499 Free PMC article. - Expression of Survivin, CK7, ASH1, HMGB3, L587S, and CLCA2 in Peripheral Blood of Lung Cancer Patients by Real-Time Polymerase Chain Reaction.
Gupta S, Gupta M, Goyal B, Yadav SRM, Mirza AA, Gupta A, Rao S, Kumari K, Nanda S, Kotru M. Gupta S, et al. Cureus. 2024 Jul 12;16(7):e64386. doi: 10.7759/cureus.64386. eCollection 2024 Jul. Cureus. 2024. PMID: 39130876 Free PMC article. - Integrative and comprehensive pan-cancer analysis of ubiquitin specific peptidase 11 (USP11) as a prognostic and immunological biomarker.
Cui L, Yang L, Lai B, Luo L, Deng H, Chen Z, Wang Z. Cui L, et al. Heliyon. 2024 Jul 11;10(14):e34523. doi: 10.1016/j.heliyon.2024.e34523. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39114046 Free PMC article. - Machine-learning and scRNA-Seq-based diagnostic and prognostic models illustrating survival and therapy response of lung adenocarcinoma.
Cheng Q, Zhao W, Song X, Jin T. Cheng Q, et al. Genes Immun. 2024 Oct;25(5):356-366. doi: 10.1038/s41435-024-00289-0. Epub 2024 Jul 29. Genes Immun. 2024. PMID: 39075270 - The prognosis, chemotherapy and immunotherapy efficacy of the SUMOylation pathway signature and the role of UBA2 in lung adenocarcinoma.
Yu L, Lin N, Ye Y, Zhuang H, Zou S, Song Y, Chen X, Wang Q. Yu L, et al. Aging (Albany NY). 2024 Feb 23;16(5):4378-4395. doi: 10.18632/aging.205594. Epub 2024 Feb 23. Aging (Albany NY). 2024. PMID: 38407971 Free PMC article.
References
- Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest. 2007;132:185–192. - PubMed
- Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B. 1995;57:289–300.
- Hochreiter S, Clevert DA, Obermayer K. A new summarization method for Affymetrix probe level data. Bioinformatics. 2006;22:943–949. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous